Loading...
Loading...
Browse all stories on DeepNewz
VisitHow will health organizations respond to HRT and Alzheimer's risk study by end of 2025?
Issue new warnings • 25%
Conduct further studies • 25%
Dismiss the findings • 25%
No official response • 25%
Official statements or guidelines from health organizations like the WHO or national health departments
Study Links Common Sleep Medications to Impaired Brain Cleansing and 60% Increased Alzheimer's Risk for APOE e4 Gene Carriers
Jan 9, 2025, 07:05 AM
Recent studies indicate that sleep plays a crucial role in the brain's ability to remove waste, functioning as a 'rinse cycle' that flushes out toxins accumulated during wakefulness. However, research conducted on mice has found that certain common sleeping medications may hinder this cleansing process, potentially increasing the risk of Alzheimer's disease. Specifically, some of the most widely used sleep aids in Spain have been linked to brain damage and a higher likelihood of Alzheimer's. Additionally, a study highlighted that women taking Hormone Replacement Therapy (HRT) and possessing the APOE e4 gene may face a 60% increased risk of Alzheimer's-related markers. The findings underscore the importance of understanding the implications of sleep aids and hormone treatments on brain health.
View original story
Criticize or oppose • 25%
Support and endorse • 25%
Neutral stance • 25%
No official response • 25%
Oppose changes • 25%
Neutral stance • 25%
No official stance • 25%
Support changes • 25%
Criticize the study's findings • 25%
No statement issued • 25%
Support the study's findings • 25%
Call for further research • 25%
No significant response • 25%
Critical • 25%
Neutral • 25%
Supportive • 25%
Centers for Disease Control and Prevention (CDC) • 25%
World Health Organization (WHO) • 25%
Other • 25%
National Institutes of Health (NIH) • 25%
Yes • 50%
No • 50%
Acknowledgement • 25%
Denial • 25%
Legal action • 25%
No comment • 25%
No significant change • 25%
Increased trust • 25%
Decreased trust • 25%
Mixed responses • 25%
Other response • 25%
Remain neutral • 25%
Oppose the proposal • 25%
Support the proposal • 25%
EMA • 25%
Other • 25%
FDA • 25%
Pfizer • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Guidelines promote alternative treatments • 25%
Guidelines suggest caution • 25%
Guidelines recommend against use • 25%
Guidelines remain unchanged • 25%